Literature DB >> 2541915

Identification of the residues in human CD4 critical for the binding of HIV.

J Arthos1, K C Deen, M A Chaikin, J A Fornwald, G Sathe, Q J Sattentau, P R Clapham, R A Weiss, J S McDougal, C Pietropaolo.   

Abstract

The CD4 molecule is a T cell surface glycoprotein that interacts with high affinity with the envelope glycoprotein of the human immunodeficiency virus, HIV, thus serving as a cellular receptor for this virus. To define the sites on CD4 essential for binding to gp120, we produced several truncated, soluble derivatives of CD4 and a series of 26 substitution mutants. Quantitative binding analyses with the truncated proteins demonstrate that the determinants for high affinity binding lie solely with the first 106 amino acids of CD4 (the V1 domain), a region having significant sequence homology to immunoglobulin variable regions. Analysis of the substitution mutants further defines a discrete binding site within this domain that overlaps a region structurally homologous to the second complementarity-determining region of antibody variable domains. Finally, we demonstrate that the inhibition of virus infection and virus-mediated cell fusion by soluble CD4 proteins depends on their association with gp120 at this binding site.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541915     DOI: 10.1016/0092-8674(89)90922-7

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  118 in total

1.  Structural features of nectin-2 (HveB) required for herpes simplex virus entry.

Authors:  W M Martinez; P G Spear
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding.

Authors:  E C Hsu; R E Dörig; F Sarangi; A Marcil; C Iorio; C D Richardson
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques.

Authors:  Timothy Fouts; Karla Godfrey; Kathryn Bobb; David Montefiori; Carl V Hanson; V S Kalyanaraman; Anthony DeVico; Ranajit Pal
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

4.  Internalization of CD4 molecules in human T-cells demonstrated by immuno-electron microscopy.

Authors:  J J Wang; C Hu; F Lee; M F Shaio; L K Chen
Journal:  Histochemistry       Date:  1992

Review 5.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

Review 6.  The use of particle concentration fluorescence immunoassay technology for the analysis of rDNA products.

Authors:  B J Del Tito
Journal:  J Ind Microbiol       Date:  1991-09

7.  Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein.

Authors:  Shi-Hua Xiang; Peter D Kwong; Rishi Gupta; Carlo D Rizzuto; David J Casper; Richard Wyatt; Liping Wang; Wayne A Hendrickson; Michael L Doyle; Joseph Sodroski
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Identification of three distinct allelic forms of bovine CD4.

Authors:  W I Morrison; C J Howard; C J Hinson; N D MacHugh; P Sopp
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

9.  Functional epitope analysis of the human CD4 molecule: antibodies that inhibit human immunodeficiency virus type 1 gene expression bind to the immunoglobulin CDR3-like region of CD4.

Authors:  M Benkirane; M Hirn; D Carrière; C Devaux
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  The cytoplasmic tail of CD4 is required for inhibition of human immunodeficiency virus type 1 replication by antibodies that bind to the immunoglobulin CDR3-like region in domain 1 of CD4.

Authors:  M Benkirane; H Schmid-Antomarchi; D R Littman; M Hirn; B Rossi; C Devaux
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.